Clozapine-induced myocarditis after long-term treatment: Case presentation and clinical perspectives

Journal of Psychopharmacology

Volumn 22, Issue 5, 2008, Pages 576-580

  Lang, U E ^a   Willbring, M ^b   Von Golitschek, R ^c   Schmeisser, A ^b   Matschke, K ^b   Tugtekin, S Malte ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b University Heart Center Dresden   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Amisulpride; Cardiomyopathy; Clozapine; Myocarditis; Olanzapine; Quetiapine; Schizophrenia; Treatment resistant

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; FLUPENTIXOL; INOTROPIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; CASE REPORT; CLINICAL FEATURE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HUMAN; LONG TERM CARE; MALE; MYOCARDITIS; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYMPTOM;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DIBENZOTHIAZEPINES; HUMANS; MALE; MIDDLE AGED; MYOCARDITIS; SCHIZOPHRENIA; SULPIRIDE;

EID: 49349099464     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107082136     Document Type: Review

References (53)

1. Bandelow B., Degner D., Kreusch U., Ruther E. (1995) Myocarditis under therapy with clozapine. Schizophr Res 17: 293-294
2. Beelen A.P., Yeo K.T., Lewis L.D. (2001) Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum Exp Toxicol 20: 215-219
3. Breier A., Buchanan R.W., Kirkpatrick B., Davis O.R., Irish D., Summerfelt A., Carpenter W.T. (1994) Clozapine in schizophrenic outpatients: effects on positive and negative symptoms. Arch Gen Psychiatry 151: 20-26
4. Buckley N.A., Sanders P. (2000) Cardiovascular adverse effects of antipsychotic drugs. Drug Saf 23: 215-228
5. Buckley P.F., Goldstein J.M., Emsley R.A. (2004) Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. Schizophr Res 66: 143-150
6. Casey D.E., Daniel D.G., Wassef A.A., Tracy K.A., Wozniak P., Sommerville K.W. (2003) Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 28: 182-192
7. Chakos M., Lieberman J., Hoffman E., Bradford D., Sheitman B. (2001) Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 158: 518-526
8. Chan J., Sweeting M. (2006) Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence. J Psychopharmacol Epub
9. Coulter D.M., Bate A., Meyboom R.H., Lindquist M., Edwards I.R. (2001) Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 322: 1207-1209
10. de Knijff D.W., Schepers P.H., Blanken-Meijs J.T. (2001) Cardiomyopathy during clozapine therapy. Ned Tijdschr Geneeskd 145: 1697-1699
11. Dossenbach M R K, Beuzen J.N., Avnon M., Belmaker R.H., Elizur A., Mark M., Munitz H., Schneidman M., Shoshani D., Kratky P., Grundy S.L., Tollefson G.D. (2000) The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. Clin Ther 22: 1021-1034
12. Duggal H.S., Mendhekar D.N. (2006) High-dose aripiprazole in treatment-resistant schizophrenia. J Clin Psychiatry 67: 674-675
13. Dursun S.M., Deakin J.F. (2001) Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol 15: 297-301
14. Emsley R.A., Raniwalla J., Bailey P.J., Jones A.M. (2000) A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 15: 121-131
15. Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., Moller H.J., WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 2: long-term treatment of schizophrenia (2006). World J Biol Psychiatry 7: 5-40
16. Green A.I., Burgess E.S., Dawson R., Zimmet S.V., Strous R.D. (2003) Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res 60: 81-85
17. Haas S.J., Hill R., Krum H., Liew D., Tonkin A., Demos L., Stephan K., McNeil J. (2007) Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 30: 47-57
18. Hedges D.W., Jeppson K.G. (2002) New-onset seizure associated with quetiapine and olanzapine. Ann Pharmacother 36: 437-439
19. Henderson D.C., Nasrallah R.A., Goff D.C. (1998) Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. J Clin Psychiatry 59: 585-588
20. Heresco-Levy U., Javitt D C., Ebstein R., Vass A., Lichtenberg P., Bar G., Catinari S., Ermilov M. (2005) D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 57: 577-585
21. Jensen V.E., Gotzsche O. (1994) Allergic myocarditis in clozapine treatment. Ugeskr Laeger 156: 4151-4152
22. Kakar P., Millar-Craig M., Kamaruddin H., Burn S., Loganathan S. (2006) Clozapine induced myocarditis: a rare but fatal complication. Int J Cardiol 112: 5-6
23. Kane J M., Honigfeld G., Singer J., Meltzer H.Y., the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789-779
24. Kane J.M., Khanna S., Rajadhyaksha S., Giller E. (2006) Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 21: 21-28
25. Karunakaran K., Tungaraza T.E., Harborne G. (2007) Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia? J Psychopharmacol 21 (4). 453-456
26. Kerwin R.W., Bolonna A.A. (2004) Is clozapine antisuicidal? Expert Rev Neurother 4: 187-190
27. Kerwin R.W., Bolonna A. (2005) Management of clozapine-resistant schizophrenia. Adv Psychiatr Treat 11: 101-106
28. Killian J.G., Kerr K., Lawrence C., Celermajer D.S. (2000) Myocarditis and cardiomyopathy associated with clozapine. Lancet 354: 1841-1845
29. Kontaxakis V.P., Havaki-Kontaxaki B.J., Ferentinos P.P., Paplos K.G., Soldatos C.R. (2006) Switching to amisulpride monotherapy for treatment-resistant schizophrenia. Eur Psychiatry 21: 214-217
30. Lee S.Y., Kim Y.J., Kim K.T., Choe H., Jo S.H. (2006) Blockade of HERG human K+ channels and IKr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine. Br J Pharmacol 148: 499-509
31. Lerner V., Chudakova B., Kravets S., Polyakova I. (2000) Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report. Clin Neuropharmacol 23: 284-286
32. Lerner V., Libov I., Kotler M., Strous R.D. (2004) Combination of 'atypical' antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry 28: 89-98
33. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. (2005) Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223
34. Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Casey D.E., Davis J.M., Kane J.M., Lieberman J.A., Schooler N.R., Covell N., Stroup S., Weissman E.M., Wirshing D.A., Hall C.S., Pogach L., Pi-Sunyer X., Bigger J.T. Jr, Friedman A., Kleinberg D., Yevich S.J., Davis B., Shon S. (2004) Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161: 1334-1349
35. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K., CATIE Investigators (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163: 600-610
36. Meeker J.E., Herrmann P.W., Som C.W., Reynolds P.C. (1992) Clozapine tissue concentrations following an apparent suicidal overdose of Clozaril. J Anal Toxicol 16: 54-56
37. Meltzer H.Y. (2005) Suicide in schizophrenia, clozapine, and adoption of evidence-based medicine. J Clin Psychiatry 66: 530-533
38. Meyer-Linden Serg A., Gruppe H., Bauer U., Lis S., Krieger S., Gallhofer B. (1997) Improvement of cognitive function in schizophrenic patients recolving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry 30: 35-42.
39. National Institute for Clinical Excellence (2002) Clinical Guideline 1. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. NICE, London
40. Raskin S., Durst R., Katz G., Zislin J. (2000) Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia. J Clin Psychopharmacol 20: 500-503
41. Reinders J., Parsonage W., Lange D., Potter J.M., Plever S. (2004) Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust N Z J Psychiatry 38: 915-922
42. Rey J.M., Walter G. (1997) Half a century of ECT use in young people. Am J Psychiatry 154: 595-602
43. Shaw P., Sporn A., Gogtay N., Overman G.P., Greenstein D., Gochman P., Tossell J.W., Lenane M., Rapoport J.L. (2006) Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 63: 721-730
44. Tiihonen J., Hallikainen T., Ryynanen O.P., Repo-Tiihonen E., Kotilainen I., Eronen M., Toivonen P., Wahlbeck K., Putkonen A. (2003) Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 54: 1241-1248
45. Tollefson G D, Birkett M A, Kiesler G M, Wood A J, Lilly Resistant Schizophrenia Study Group (2001) Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 49: 52-63
46. Vaddadi K.S., Soosai E., Vaddadi G. (2003) Low blood selenium concentrations in schizophrenic patients on clozapine. Br J Clin Pharmacol 55: 307-309
47. Volavka J., Czobor P., Sheitman B., Lindenmeyer J.P., Citrome L., McEvoy J.P., Cooper T.B., Chakos M., Lieberman J.A. (2002) Clozapine, olanzapine, risperidone and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 159: 255-262
48. Walker A.M., Lanza L.L., Arellano F., Rothman K.J. (1997) Mortality in current and former users of clozapine. Epidemiology 8: 671-677
49. Wooltorton E. (2002) Antipsychotic clozapine (Clozaril). myocarditis and cardiovascular toxicity. CMAJ 166: 1185-1186
50. Ziegenbein M., Calliess I.T. (2006) Clozapine and ziprasidone: a useful combination in patients with treatment-resistant schizophrenia. J Neuropsychiatry Clin Neurosci 18: 246-247
51. Ziegenbein M., Kropp S., Kuenzel H.E. (2005) Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. Clin Neuropharmacol 28: 220-224
52. Zink M. (2006) Optimizing the antipsychotic potency of olanzapine by augmentation-a critical review. Psychiatr Prax 33: 261-268
53. Zink M., Mase E., Dressing H. (2004) Ziprasidone-augmentation of clozapine. Psychiatr Prax 31: 259-261